Servier’s medicines treat patients in close to 140 countries.
Servier invests close to 20% of revenue from brand-name medicines in R&D each year.
Servier Group
SERVIER GROUP
Committed to therapeutic progress to serve patient needs
At Servier, we draw strength from our independence. Being free to make our own strategic decisions and adopt a long-term vision enables us to fulfill our vocation as a Group committed to therapeutic progress to serve patient needs. We focus on the needs of patients and health care professionals, working closely with them on innovations while constantly considering our impact on society and the environment.
Together, we are inventing health care for today and into the future.
Our special status as a laboratory governed by a foundation means each year, we can invest close to 20% of our revenue from brand-name medicines in research and development, a strategy that helps us to discover new treatments more easily.
Day in, day out, we capitalize on the talent and engagement of over 22,000 people employed throughout our Group in order to make our brand-name and generic medicines available to patients in close to 140 countries.
These medicines are the fruit of our knowledge and expertise in our therapeutic areas of oncology, cardiometabolism & venous diseases, neurology.
20%
Close to 20% of revenue from brand-name medicines invested in R&D each year
00:00 / 00:00
Servier engages in open innovation to tackle the health challenges facing society, now and in the future. We work fervently alongside our partners, including academic researchers, start-ups, pharmaceutical groups and biotech companies.
We also endeavor to drive scientific progress by working with patients at every stage of the medicine life cycle. Ever attentive to patient needs and experiences, we place them at the heart of our approach to innovation within virtuous ecosystems.
This collective energy enables us to pick up the pace of therapeutic innovation to serve patients, to serve life.
Did you know?